Collagen Hybridizing Peptides Suggest a Correlation Between Collagen Degradation in and Recruited Inflammatory Cells in MI

Our In Vivo CHPs are conjugated with sCy 7.5 for near-IR detection. Contact us for customized conjugates.

Contact Us
Understanding Myocardial Infarction


Myocardial Infarction (MI), commonly known as a heart attack, is a critical cardiovascular event resulting from the interruption of blood flow to a part of the heart muscle, leading to cell death and tissue damage. Primarily caused by the rupture of atherosclerotic plaques within coronary arteries, MI affects millions globally, with significant morbidity and mortality. According to the World Health Organization, around 17.9 million people die annually from cardiovascular diseases, with MI being a leading contributor.

One of the crucial yet often overlooked consequences of MI is damage to the heart's collagen matrix. The collagen matrix, a structural network providing mechanical support and integrity to the cardiac tissue, undergoes significant degradation during and after an infarction. This degradation results from an inflammatory response, where enzymes such as matrix metalloproteinases (MMPs) are activated, breaking down collagen fibers. The loss of this structural framework impairs the heart's ability to function efficiently, leading to adverse remodeling, heart failure, and reduced quality of life for survivors.

Understanding the impact on the collagen matrix is essential for developing targeted therapies aimed at mitigating these detrimental effects and improving patient outcomes.

Current Treatment Challenges
Current treatment challenges in myocardial infarction (MI) research are multifaceted, reflecting the complex nature of the condition. While immediate revascularization strategies, such as percutaneous coronary intervention (PCI), have significantly improved survival rates, long-term outcomes remain problematic due to adverse cardiac remodeling. A key issue is the damage to the heart's collagen matrix during and after an MI. The collagen matrix, crucial for maintaining the structural integrity of cardiac tissue, is severely compromised by the inflammatory response and the activity of matrix metalloproteinases (MMPs) that degrade collagen fibers. This degradation leads to weakened cardiac structure, promoting pathological remodeling, fibrosis, and eventually heart failure. Current therapeutic approaches largely focus on managing symptoms and preventing further ischemic events but often fall short in addressing the underlying damage to the collagen matrix. Developing treatments that can effectively protect and restore the collagen matrix is a significant challenge. Novel strategies, including the use of MMP inhibitors, regenerative medicine, and bioengineered scaffolds, are under investigation, aiming to preserve or restore the structural integrity of the heart post-MI. However, translating these innovations from bench to bedside requires overcoming substantial scientific, clinical, and regulatory hurdles.
Why CHPs?
Collagen Hybridizing Peptides (CHPs) are vital in myocardial infarction (MI) research because they specifically bind to denatured collagen, allowing precise detection and targeting of damaged areas. After an MI, the collagen matrix in the heart undergoes significant degradation, leading to adverse remodeling and heart failure. CHPs enable the visualization and quantification of this collagen damage, providing critical insights into the extent of matrix degradation and facilitating the development of therapies aimed at preserving or restoring the structural integrity of cardiac tissue​